Obinutuzumab 1g/40ml solution for infusion vials
NHS hospitals in England used £44,938,127 of indicative cost of Obinutuzumab 1g/40ml solution for infusion vials in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 3.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Obinutuzumab 1g/40ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Obinutuzumab 1g/40ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Southend Univ Hosp Nhs Foundation Trust | £1,705,680 |
| Royal Devon & Exeter Nhs Foundation Trst | £1,559,290 |
| United Lincolnshire Hospitals Nhs Trust | £1,367,856 |
| Hull And East Yorkshire Hpls Nhs Trust | £1,261,872 |
| The Clatterbridge Cancer Centre Nhs Ft | £1,189,008 |
| Western Sussex Hospitals Nhs Found Trust | £1,175,760 |
| University College London Foundation Tr | £924,048 |
| Salford Royal Nhs Foundation Trust | £874,368 |
| Frimley Health Nhs Foundation Trust | £871,387 |
| Nottingham University Hospitals Trust | £857,808 |
The primary-care picture
Obinutuzumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Obinutuzumab medicine page.